Highlight
This study identifies two age-independent immunological subtypes in new-onset type 1 diabetes patients, each with unique transcriptomic signatures, immune cell phenotypes, and differential responses to immunotherapies such as anti-CD20 and CTLA4-Ig. These subgroups also show significant variation in post-onset C-peptide decline rates, underscoring their relevance to disease progression and treatment efficacy.
